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Abstract Every day, analytical and bio-analytical chemists
make sustained efforts to improve the sensitivity, specificity,
robustness, and reproducibility of their methods. Especially in
targeted and non-targeted profiling approaches, including
metabolomics analysis, these objectives are not easy to
achieve; however, robust and reproducible measurements
and low coefficients of variation (CV) are crucial for success-
ful metabolomics approaches. Nevertheless, all efforts from
the analysts are in vain if the sample quality is poor, i.e. if
preanalytical errors are made by the partner during sample
collection. Preanalytical risks and errors are more common
than expected, even when standard operating procedures
(SOP) are used. This risk is particularly high in clinical stud-
ies, and poor sample quality may heavily bias the CV of the
final analytical results, leading to disappointing outcomes of
the study and consequently, although unjustified, to critical
questions about the analytical performance of the approach
from the partner who provided the samples. This review fo-
cuses on the preanalytical phase of liquid chromatography–
mass spectrometry-driven metabolomics analysis of body
fluids. Several important preanalytical factors that may seri-
ously affect the profile of the investigated metabolome in
body fluids, including factors before sample collection, blood
drawing, subsequent handling of the whole blood (transporta-
tion), processing of plasma and serum, and inadequate condi-
tions for sample storage, will be discussed. In addition, a de-
tailed description of latent effects on the stability of the blood
metabolome and a suggestion for a practical procedure to
circumvent risks in the preanalytical phase will be given.
Keywords Metabolomics . Preanalytical . Bias . Blood .
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Introduction
Metabolomics delineates biological phenotypes by profil-
ing changes of endogenous metabolites [1]. In the past
decade, metabolomics has been proved to be a valuable
tool in translational medical research; it led to the detection
of novel biomarkers for diagnosis, prognosis, and person-
alized medicine [2–5], and functional metabolomics stud-
ies elucidated novel pathomechanisms. Of note, although
often described in a diagnostic context, functional bio-
markers (lysophosphatidylcholines, amino acids, etc.) en-
able deeper insights into pathomechanisms but do not ful-
fill the criteria for diagnostic use, for example high diag-
nostic specificity. The most common biological specimens
used in clinical metabolomic studies are body fluids and
tissues [6]. Recent studies revealed the possibility of using
tissue metabolomics as a reference for clinical resection, to
distinguish malign from normal tissue [7]. For the discov-
ery of novel diagnostic and/or functional biomarkers,
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noninvasive or less-invasive collected body fluids are usu-
ally used. As well as blood and urine, other body fluids
including saliva [8–10], cerebrospinal fluid [11–13], feces
[14–16], and follicular fluid [17, 18] are investigated in
clinical metabolomics projects.
Both blood and urine are regarded as a Bpool^ of the me-
tabolome. Urine contains many metabolic end products and
metabolites that, e.g., originate from metabolized nutrients,
drugs, and xenobiotics, etc. [19–22], whereas most metabo-
lites in blood reflect the endogenous metabolites. Hence, the
joint metabolomics analysis of blood and urine could provide
complementary data reflecting the state of the whole system at
a defined time point.
However, traditionally the collection and storage of blood
samples in biobanks has been more common than collection
of urine. One reason is that the 24 h collection of urine is
cumbersome for the study subject and error-prone, and much
more intrusive than the little effort necessary to draw blood.
Furthermore, in spot urine the concentration of compounds is
closely related to the individual intake of liquid, which makes
adjustment, in particular of very diluted or highly concentrated
urine, difficult. However, a limitation of blood samples is the
risk of highly dynamic and pronounced changes of the metab-
olome in vitro, i.e. in the sample tube after blood drawing.
Therefore, this pre-analytical phase needs to be tightly con-
trolled and perfectly regulated during blood collection to
avoid any negative effects on the metabolite pattern. This pro-
cess is usually tightly regulated by a standard operation pro-
cedure (SOP) [23].
In complex clinical studies the blood collection is com-
monly described as the easy part. However, this easy part
may greatly affect the sample quality and therefore the success
of the study. Frequently, the actual quality of samples collect-
ed in a clinical study and used for metabolomics is an
underestimated disadvantage. In particular, in multicenter
studies it is still a major challenge to ensure that every hospital
strictly follows the entire preanalytical procedure defined in an
SOP. Care must also be taken that already existing SOPs are
checked before the start of a metabolomics project for their
general applicability, to ensure they are suitable for sample
collection for omics approaches. For example, with the objec-
tive of achieving consistent conditions between different hos-
pitals, a guideline for the collection of blood samples for a
breast-cancer clinical trial recommended completing the pro-
cess, from phlebotomy to storage of the samples in a freezer,
within 8 h [24]. However, after vein puncture the blood cells
should be removed and the plasma or serum preserved in a
refrigerator as soon as possible (for details see section BThe
handling of whole blood after drawing^). The ultimate objec-
tive for blood collection in the context of omics studies (and
many others) is to define the safety margin for sample han-
dling after blood drawing, including establishing a procedure
to ensure sample quality [25, 26]. However, frequently the
daily clinical routine or individual local limitations, for exam-
ple no direct access to a centrifuge at the place where the blood
is drawn, impede the fulfillment of perfect pre-analytical pro-
cedures. Hence compromises need to be made between per-
fect preanalytical processing, the feasibility in the clinical
study, and possible preanalytical effects on analytes. Accord-
ingly, the generation of a feasible SOP is a challenging task
which can only be realized through close collaboration of the
clinical scientists and pre-analytical experts.
This review will report critical aspects of the preanalytical
phase for clinical metabolomics studies, with a special focus
on the sampling of blood. Generalized preanalytical aspects
including relevant factors before sample collection, material
preparation (tubes etc.), and collection, transportation, and
storage of blood specimens are discussed. Practical sugges-
tions and recommendations to circumvent and avoid
preanalytical problems will be presented.
Metabolomics and clinical applications
The measurement of blood metabolites in clinical settings
has a long history. For decades many different metabolites,
including glucose, creatinine, acylcarnitines, urea, uric ac-
id, ammonia, bilirubin, bile acids, cholesterol, amino acids,
fatty acids, and many others, have been used in clinical
chemical laboratories to investigate the state of health
[27, 28]. Now, by use of metabolomics, thousands of en-
dogenous and exogenous compounds in blood with differ-
ent chemical and physical properties and biological stabil-
ities can be profiled at the same time [29]. Complementary
targeted and non-targeted-analysis metabolomics is an im-
portant technique for systems biology and translational
medicine, in particular in combination with transcriptomics
and/or proteomics investigations [30, 31].
An important aspect of clinical metabolomics is the eluci-
dation of biomarkers for the diagnosis and prognosis of dis-
ease, and the subsequent investigation of their function in
projects of translational medicine. Early detection of disease
is of great importance for the prognosis of the patient, espe-
cially for chronic and serious diseases including cancer, dia-
betes, and cardiovascular disease [32–35]. A common strategy
for the identification of novel biomarkers includes two steps:
discovery and validation. In the discovery step, profiling of a
broad range of metabolites in a small set of samples is per-
formed by a non-targeted metabolomics approach with the
objective of detecting potential biomarkers [36]. In the subse-
quent validation step, targeted measurement of the elucidated
potential biomarkers is applied to a large sample set to study
the diagnostic power (sensitivity, specificity, robustness, etc.).
This strategy is also suitable for the investigation of prognostic
and other types of biomarker [36, 37].
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Figure 1 illustrates the steps of a non-targeted clinical meta-
bolomics study from the preanalytical phase to the final inter-
pretation of the data:
1. Design the experiment (see section BPreparation before
blood collection^). This step should include joint discus-
sion by medical researchers, preanalytical experts, and
analytical (bio)chemists to draft and define the SOPs. Be-
cause samples are usually collected and temporarily
stored by nurses, medical students, or doctors, this point
requires intensive discussion to adapt and optimize the
SOP, focused on the local practicability in accordance
with the preanalytical quality management to ensure sam-
ple quality. Further steps at this stage are designing the
study, performing biostatistics defining the number of
samples needed, drafting a questionnaire for the study
subjects (if necessary), and finally applying for ethical
clearance.
2. Collection of biological samples according to the SOP
(please find a recommendation in the section
BPreanalytical SOP for blood in metabolomics^).
3. Preparation of samples. Sample preparation includes pro-
tein removal and metabolite extraction (see section
BSample pretreatment for mass-spectrometry analysis^).
This is a crucial step in the analytical process, because the
categories of metabolite to be measured are specified by
this pretreatment step [38]. Steps 1–3 are so-called
preanalytical steps.
4. Instrumental analysis. Mass spectrometry (MS) and nu-
clear magnetic resonance (NMR) are the commonly used
methods.
5. Data processing. The data collected from the instrument
are usually multidimensional and include interference
from chemical noise. The data-processing procedure com-
monly includes data reduction, denoising, metabolite ex-
traction, and alignment [39].
6. Interpretation of the results. In this step, the chemical
structures of the potential biomarkers should be identified,
especially for the MS-based analytical techniques. If
systems-biology approaches were used and multi-omics
data need to be combined and evaluated for pathway vi-
sualization and enrichment, sophisticated software tools,
for example InCroMAP, are needed [40].
It is important to note that an error-prone preanalytical
phase unavoidably leads to poor, possibly misleading results;
in such cases all efforts by the analytical (bio)chemist to en-
hance accuracy, sensitivity, and specificity in the analytical
phase cannot compensate for the preanalytical errors and are
consequently in vain and a waste of time.
Preparation before blood collection
The metabolite pattern in blood is a tightly controlled homeo-
static system, but a variety of physiological conditions and
exogenous factors may lead to dynamic changes. As well as
the possible substantial effects of the preanalytical phase [25],
the composition of the blood metabolome is also affected by
multiple intrinsic and extrinsic factors, including circadian and
physiological rhythm [41], diet [21], exercise [42], drugs [43],
and others [44] (Table 1). For this reason, well-considered
preparation of the study subjects is needed before sample col-
lection for metabolomics studies.
Sex difference is a relevant and important factor in meta-
bolomics studies [45, 59] (Table 1). Ishikawa et al. studied the
plasma-lipid profiles of men and women of different ages, and
reported a bigger difference between older males and females
[45, 46]. Lawton et al. measured 300 compounds in 269 indi-
viduals and found that the concentrations of more than 100
metabolites were related to age [47]. Hence, to avoid age-
related bias in metabolomics, results-matching for age is rec-
ommended. BMI is also an important factor in metabolomics
studies. Morris et al. summarized the association between
BMI and metabolomics profiles [49]. With the exception of
lipids, branch-chain amino acids (BCAA) were reported to be
the metabolites most closely related to BMI [49]. Consequent-
ly, it is of great importance for the study design to take into
account age, sex, and BMI, and kidney and liver function etc.,
and to match the subjects regarding such factors (Table 1).
Fasting, according to clinical regulations, is recommended
before sample collection, because themetabolite profile in blood
undergoes dynamic changes during a period of several hours
after meals [53, 60]. For example, 3 and 5 h postprandial the
levels of essential amino acids and acylcarnitines change signif-
icantly [53]. It is therefore necessary to establish which interval
Fig. 1 Scheme of the main steps in a clinical metabolomics study. The
pre-analytical procedures are given on the left-hand side
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without food intake is suitable. For the oral-glucose tolerance
test at least 8 h and for the measurement of triglycerides and
homocysteine 9–12 h fasting is recommended [54]. In Table 1
we recommend 12 h fasting, on the basis of long-established
recommendations for medical examination of metabolic func-
tions which have been revealed to be also suitable for metabo-
lomics studies [53, 54]. Furthermore, a study by Winnike et al.
revealed that one-day dietary standardization before sample col-
lection can normalize the effect of food intake [61].
Physical exercise, stress, and several lifestyle aspects are
also important factors affecting the blood metabolome and
should be avoided before blood collection. Exercise may lead
to increases in levels of lactate, some amino acids, and
acylcarnitines, and to decrease of fatty acids etc. [53, 58,
62]. Furthermore, lifestyle factors including smoking also
led to a clear separation of the metabolic profiles in blood in
a comparison of cigarette smokers and nonsmokers [63].
Thus, matching lifestyles of the participants of a study on
the basis of the information in a questionnaire could be an
effective strategy to minimize avoidable bias of the results.
Blood is not only collected in the morning, but sometimes
also at other times of day, e.g. in huge epidemiological pro-
jects, for example national cohort studies. Therefore the ques-
tion arises as to whether the circadian rhythm affects the
blood. In the results of Ang et al., 19 % (203/1069) of metab-
olite changes had significant time-of-day differences [56]; 34
affected metabolites were identified, including carnitines,
LPCs, LPEs, bilirubin, cortisol, and amino acids [56].
Dallmann et al. reported that lipids are closely associated with
the biorhythm, which may be, at least to some extent, related
to food intake [64]. Branched amino acids and lactate were
also found to be affected by the biorhythm [64]. Hence, the
light–dark cycle, sleep–awake rhythm, time point, composi-
tion of last food intake, etc. should also be taken in account,
and studies should avoid mixing samples collected at different
times of day, at least for metabolomics studies.
Other very common, important factors affecting the metab-
olism, and the outcome of metabolomics studies, are drugs.
The intake of drugs should be established in the questionnaire,
because otherwise metabolic effects of drugs may be
misinterpreted as findings relevant to the experiment. In par-
ticular, in studies investigating individuals aged above
45 years the daily use of drugs is commonly a factor. For
example, new and unexpected findings in a lipidomics study
may also be caused by a mismatch in the study population of
subjects taking statins. Other, often less-considered factors
affecting the metabolome are dietary supplements, including
fish-oil capsules, multivitamin preparations, amino-acid and
protein shakes, etc. Supplements are often less reported in
questionnaires by the study subjects because these compounds
are not drugs and are not regarded as substances affecting the
results of the study. However, the effects of these supplements
on metabolomics results may always be present in human
studies, and the possible misinterpretation of the acquired data
is not to be underestimated. Therefore, in the study question-
naire dietary supplements and drugs must be included and this
information should be also reported to the analytical chemists.
Table 1 summarizes factors affecting the outcome of meta-
bolomics studies that should be considered before sample col-
lection, i.e. in the study design and sample-collection proce-
dure, to avoid misleading results and the reporting of useless
biomarkers.
Table 1 Factors affecting the outcome ofmetabolomics studies that should be considered before sample collection, i.e. in the study design and sample-
collection procedure
Factor Recommendations Main metabolites and references (selected examples)
Sexa Match the distribution of sex Lipids [45, 46], orthophosphate, α-tocopherol, creatinine,
DHEA-S [47], cholesterol [44]
Age Match the distribution of age Amino acids [48], isocitrate, succinate, malate, lactate, etc. [47]
Body mass index (BMI) Refer to BMI before the enrollment
of participants, and match for BMI
BCAA [49–51], lipids, steroids [52]
Fasting and feeding 12 h fasting (usually overnight) Essential amino acids and acylcarnitines [53], triglycerides
and homocysteine [54]
Circadian rhythm Keep normal biorhythm; collect
samples at the same time point
(usually in the morning); take
circadian rhythm into account
if metabolite concentrations
follow a rhythm
Lipids [55], BCAA, lactate [56], bilirubin, cortisol [56, 57]
Exercise; stress Avoid unaccustomed physical activity;
avoid stress before drawing blood
Lactate, free fatty acids, glucose, amino acids and acylcarnitines
[53, 58], uric acid [44], creatinine and many others
Drugs and/or nutritional supplements
(e.g. vitamins, amino acids)
At least 12 h abstention, preferably
24 h or longer
–
a Sex-specific differences in metabolite concentrations should always be assumed until proved otherwise
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The selection of blood-collection tubes
The development of modern analytical MS instruments has
enabled highly sensitive analysis of metabolites, but this is
associated with a higher sensitivity to chemical noise signals.
In comparison with other interfaces, the commonly used
electrospray ion source is more sensitive to matrix effects [65].
The blood-collection tube could be a major source of chem-
ical noise by introducing exogenous interferences into blood
samples [25]. Characteristic patterns of tube-dependent chemical
noise originating from plastic polymers in lithium-heparin sam-
ple-collection tubes are shown in Fig. 2. These interferences lead
to substantial signal suppression ofmetabolite ionmasses. On the
other hand, Korfmacher et al. reported that Li+ increases the
ionization efficiency of many metabolites [65]; however, the sig-
nals of polymers may also be increased by the use of Li-heparin
Microtainer tubes (Fig. 2). In our recent study we used plastic
sample-collection tubes with different anticoagulants, and also
detected a strong chemical noise in the Li-heparin tubes [25].
Glass collection tubesmay eliminate this problem but, justifiably,
they are not commonly used in the clinic. In conclusion, great
caution in the planning phase of a clinical metabolomics study is
advisible when selecting the sample tubes. A pretest is absolutely
mandatory, and the tubes of choicemust bemandated in the SOP.
As well as the collection of whole-blood samples in tubes, the
collection of a dried blood spot (DBS) on a filter paper is a
convenient method with a long history in the clinic. DBS is a
standard sample matrix in newborn screening to profile for
inherited diseases, because only a small volume of blood per spot
from heel prick is needed (<50 μL) [66]. Targeted metabolomics
is themethodmost often used to analyze DBS [67, 68]. DBS and
the following solvent extraction are regarded as one of the least
invasive and most efficient strategies for whole-blood-sample
collection and preparation in targeted metabolomics [67]. DBS
has also been used in some nontargeted metabolomics studies
[69, 70] and has been considered as an alternative specimen.
Another crucial point is the decision to use either plasma or
serum, which entail the use of different blood-collection tubes.
Both serum and plasma arewidely used inmetabolomics studies,
but there is an ongoing debate regarding which sample material
is better suited for metabolomics. In this context scientists should
be aware that metabolic profiles of plasma and serum are differ-
ent per se, at least to some extent (Table 2). Plasma-sample
collectors have the great advantage that the samples can be put
at once into ice water. This avoids adverse effects of exposure of
the samples to room temperature. In contrast, blood intended for
the generation of serum needs to clot at room temperature for a
defined time, usually >30 min (for details see section BThe han-
dling of whole blood after drawing^). In the serum sample, acti-
vated platelets release a variety of metabolites, lipids, and prote-
ases during the coagulation process. Denery et al. reported the
detection of more ion features in serum than in plasma, and
Fig. 2 Themass spectrum of polymers shed from Li-heparinMicrotainer
plastic tubes (Reprint from RCM (2003)17 (1):97–103, license number:
3485190734889). When pure water, blank plasma, and plasma were
added to the tubes, typical mass-spectrum patterns could be observed
which may cause significant matrix effects on MS
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significantly higher lysophosphatidylinositol signals in plasma
[78]. Biochemical studies investigating the difference between
these two matrices indicate that serum contains more proteins
[79, 80] and has characteristic peaks of peptides and increased
levels of hypoxanthine and xanthine [71, 75], thromboxane B2
[76], arginine, and LPCs [73]. Therefore, if serum is used it is of
utmost importance to use the same clotting time for all samples in
a study and to pay attention to biomarkers that may originate
from activated platelets during data evaluation. Of note, the plate-
let number may vary in the range 20,000–1,000,000 μL−1 (ref-
erence range: 150,000–450,000 μL−1) in a clinical study popu-
lation. Hence the two most probable, closely related reasons for
differences in serum and plasma metabolomes are: first, the acti-
vated platelets, which are metabolically very active and release
compounds; and second, the need to expose serum tubes to room
temperature for proper coagulation [81]. Differences between
serum and plasma are summarized in Table 2.
To generate plasma an anticoagulating supplement is needed
in the blood-collection tube. The kind of supplement used de-
pends on the diagnostic routine variables to be analyzed. The
most common anticoagulants in the clinic are ethylene diamine
tetraacetic acid (EDTA), heparin, citrate, and fluoride. Heparin
is an anti-thrombin activator, whereas EDTA and citrate chelate
calcium ions. EDTA and heparin blood-collection tubes are
commonly used in metabolomics studies, although there are
still some debates about the best additive for LC–MS-based
metabolomics. Actually, the differences in LC–MS analysis
between plasma samples generated by different anticoagulants
are not evident [71, 82], except for Li+-heparin (see above). Of
note, for NMR-driven metabolomics analysis EDTA is not
recommended because of strong noise signals [83]. For LC–
MS applications the cations in the anticoagulants are still a
subject of debate, in particular which added cations may cause
matrix effects. Barri et al. reported that sodium and potassium
formate may cause matrix effects and interferences affecting
co-eluting polar metabolites [71]. However, sodium and potas-
sium are the most common cationic additives used in plasma
blood-collection tubes. As mentioned above, the presence of
Li+ may increase the ionization efficiency of many metabolites
(Fig. 2), including phospholipids and triacylglycerols [65], but
may also increase the signals of plastic polymers and produce
serious matrix effects (Fig. 2). Therefore, Li+-heparin cannot be
recommended formetabolomics analysis.We prefer K+–EDTA
blood-collection tubes for metabolomics investigations, but as
mentioned above, a pretest of the tubes from different compa-
nies is absolutely mandatory because the kind of plastic and the
composition and purity of additives may vary.
The effect of hemolysis on the metabolome
Hemolysis is one of the major risks during blood drawing,
both in clinical studies and animal experiments [84, 85]. Al-
though it can be avoided by careful drawing and handling of
the whole-blood samples, it is the most common preanalytical
error in the clinic [86]. As well as strong aspiration there are
other causes of hemolysis, including vigorous shaking of the
tube, transportation by pneumatic post within the clinic, cen-
trifugation at too high speed, and inadequate environmental
temperature. Hemolysis causes the release of intracellular
compounds including metabolites and enzymes, which could
significantly alter the metabolite profile of the blood sample.
Lyses of erythrocytes increase the concentrations of former
intracellular metabolites, for example tryptophan, and lipids,
for example phospholipids, originating, e.g., from the cellular
membrane. Recently we revealed that approximately 18 % of
the detected ion mass signals in a non-targeted approach are
affected by hemolysis [25].
Hemolytic and non-hemolytic samples can be easily differ-
entiated by their color, because free hemoglobin changes the
color of serum or plasma from pale yellow to bright red. How-
ever, in slightly hemolytic samples this change in color is not
clearly visible, especially when the bilirubin level of the pa-
tient is also increased. Free hemoglobin can also be quantita-
tively measured by a routine two-wavelength clinical chemis-
try method (reference range: <10 mg dL−1), and this is a very
reliable method of detecting slight hemolysis compared with
qualitative visual evaluation of the sample color. As well as
hemolysis, icterus and lipemia are also common preanalytical
problems affecting the results of routine clinical tests [87]. In
contrast with routine clinical optical assays, icteric and lipemic
samples are usually no problem for LC–MS-driven metabolo-
mics analysis.
Table 2 Compounds that differ between serum and plasma
Different compounds (shown are levels in serum







Increased: lysophosphatidylcholines (LPCs), diacyl-
phosphatidylcholine, thromboxane B2, 12-HHT, 12-
HETE, eicosapentaenoic acid, only detected in sera:
11,12-diHETrE, 14,15-diHETrE, 17,18-diHETE




Increased: arginine, serine, phenylalanine, glycine,
glutamate, cystine phenylalanine, serine, ornithine,








Decreased: pyruvate, citrate, fumarate, glycerate,
urate, xylitol
[75–77]
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The handling of whole blood after drawing
Prolonged exposure of whole blood to room temperature after
drawing is another major risk of the preanalytical process.
This preanalytical error has the most pronounced effect on
the sample quality and consequently on the blood metabo-
lome. Scientists should be aware that a 9 mL tube contains
billions of metabolically active blood cells. Therefore, timely
separation of serum or plasma from blood cells is mandatory.
Of note, because for the generation of serum the whole blood
needs to clot at room temperature, the serum metabolite pro-
file may reflect the metabolic action of activated platelets (es-
sential for the coagulation process) as well as the metabolic
action of red and white blood cells and the activity of circu-
lating enzymes. Therefore, the clotting time should be
strictly controlled and serum samples exposed to different
clotting times should not be mixed for metabolomics anal-
ysis. According to results from a proteomics study by
Timms et al. [88], over-extended clotting time for serum
(over 60 min) may lead to cell lyses, whereas a clotting
time of less than 30 min leads to incomplete coagulation.
An NMR-based metabolomics study confirmed that
prolonged clotting time affects the components of the me-
tabolome [89].
In contrast with serum-sample tubes, whole blood drawn
for the generation of plasma can be put at once into iced water
after drawing. Lowered ambient temperature minimizes the
metabolic activity of cells and enzymes and keeps the metab-
olite pattern almost stable. The principle-component-analysis
(PCA) score plot given in Fig. 3 reveals no clear difference
between whole blood prepared at once (fresh) or after
2 h and 4 h storage in iced water. All samples from
the same individual clustered together regardless of the
different conditions. These findings from a non-targeted
metabolomics approach indicate that only minor changes
may occur between freshly prepared plasma sample and
whole blood placed on ice for up to 4 h [25]. In an
independent study Kamlage et al. replicated these find-
ings using a targeted approach covering 267 metabolites
in blood and 262 metabolites in EDTA plasma; the levels
of almost all metabolites were stable for up to 6 h in iced
water [90].
From the practical perspective it should be mentioned
that in most clinical studies it is feasible to separate blood
cells from plasma within 2 h, and it should be possible in
almost all studies to separate the cells from plasma within
4 h. Cooling of whole-blood samples at once in iced
water is recommended for short-term preservation before
centrifugation and separation of plasma. For the generation
of serum a strictly controlled fixed time at room temper-
ature (at least 30 min) followed by immediate cooling is
suggested.
The handling and storage of serum and plasma samples
After the separation of cells the stability of metabolites, and
hence of the metabolome, can still be affected by the presence
of enzymes and many other proteins in serum and plasma.
Hence the handling of plasma or serum is also a relevant
Fig. 3 Evaluation of blood samples placed in iced water after blood
drawing. The PCA score plot indicated no significant differences
between fresh samples and samples placed at once in iced water for 2
or 4 h. (Reprint fromClinical Chemistry (2013) 59 (5):833–845) (License
number: 3485201154760)
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preanalytical factor affecting the stability of the metabolome.
However, these changes are several orders of magnitude
less pronounced than alterations occurring in whole blood
in vitro after drawing. Exposure of plasma to room temper-
ature for 16 h resulted in slight, significant changes to
23 % of the analyzed metabolites [91]. Figure 4 shows
the effects of 1 h exposure of plasma samples to 37 °C
[91]. Plasma stored under these conditions is very unstable;
however, the exposure of plasma or serum to 37 °C during
sample processing is rather unusual. Prolonged exposure to
low temperature, in contrast, causes fewer changes of me-
tabolites. For example, when EDTA plasma is stored for
16 h at 4 °C, only 30 of 262 measured metabolites undergo
slight changes [90].
Freezing is the next step in clinical sample handling. Be-
cause of the lack of −80 °C freezers in many clinical surround-
ings, or at least a lack in close proximity, samples are often
stored at −20 °C, at least temporarily before a decision is made
by the medical doctor as to which properties should be ana-
lyzed, whether omics approaches should be used, etc. An
NMR-based metabolomics study revealed that storing plasma
at −20 °C resulted in significant changes of some metabolites,
including glucose and proline [92]. In contrast, according to
the results of a clinical chemistry study, 17 common clinical
routine analytes in serum, including such metabolites as bili-
rubin, uric acid, cholesterol, creatinine, and triglycerides, are
relatively stable when stored at −20 °C for three months [93].
However, the level of albumin changed significantly. Proteins,
in particular albumin, are essential molecules in serum or
plasma which absorb and release many small compounds,
possibly even in frozen samples. Hence changes in albumin
levels may affect the concentration of metabolites. Because of
the stability of proteins in serum or plasma, samples can be
stored at −70 °C for four years without obvious changes in the
concentration [94]. Storage of biofluids at −80 °C or below is
regarded as the preferred condition [95]. Pinto et al. found
small changes in NMR spectra of plasma metabolites after
20–30 months’ storage at −80 °C [92]; however, low-
abundance metabolites, which account for most of the metab-
olome, are not covered by NMR approaches. Yang et al. re-
ported differences between two sets of plasma stored at
−80 °C for two months and for five years [91]. These studies
provided a basis for future investigations of the stability of
frozen samples.
Fig. 4 The effect of plasma storage at 37 °C and 4 °C on serotonin, lyso-
phospholipids, and choline. LPCs underwent significant changes even at
4 °C. Serotonin and choline were easily affected when placed at 37 °C.
Reprinted with permission from Ref. [91] Copyright (2013) American
Chemical Society
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Because nontargeted metabolomics measures the relative
content of thousands of ions, it is difficult to compare the data
from different analytical batches. To this end, targeted analysis
of metabolites could provide valuable data on sample stability.
Hustad et al. studied the stability of B vitamins and metabo-
lites related to one-carbon metabolism in serum samples
stored at −25 °C for 29 years [96]. Serum amino acids varied
in stability during long-term storage at −25 °C; for example,
methionine was transformed to methionine sulfoxide. Further-
more, most B vitamins were found to be unstable during long-
term storage. However, other metabolites, including betain,
sarcosine, and creatinine, were relatively stable. Metherel
et al. studied the stability of eicosapentaenoic acid (EPA)
and docosahexaenoic acid (DHA) stored under different con-
ditions [97]. EPA and DHA levels in whole blood are stable
for at least 180 days when frozen at −75 °C. At −20 °C a
significant reduction of these two polyunsaturated fatty acids
was detected [98]. On the basis of current studies, heparin and
antioxidant may be a better choice for blood collection to
maintain the stability of EPA and DHA during long-term stor-
age [97].
The stability of the entire metabolome under long-term
storage conditions is still an open question. There is still a
big gap between the recommended ideal storage of body
fluids and the reality in daily clinical practice. Although liquid
nitrogenmight be the condition of choice, it is not feasible and
practical in many hospitals, especially in developing
countries.
The effect of freezing and thawing
Serum and plasma are believed to be relatively stable when
stored at −80 °C. However, repeated freeze–thaw cycles are
unavoidable in clinical studies dealing with a limited number
of sample aliquots. In particular, the most valuable sample
aliquots are most frequently used to answer novel research
questions, which results in rethawing and subsequent
refreezing to save this valuable sample material. Stepwise
thawing and keeping the samples at 4 °C for as short a time
as possible before refreezing is highly recommended. Howev-
er, usually samples are thawed at room temperature to save
time [92, 94, 99–101]. L-Carnitine, lipids, choline phospho-
lipids, alanine, glucose, pyruvate, and acetone changed after
four or five freeze–thaw cycles at room temperature [92, 101].
In a clinical-chemistry study, total bilirubin and uric acid were
revealed to be unstable even after one or two freeze–thaw
cycles at room temperature [92]. However, Comstock et al.
reported that cholesterol, micronutrients, and hormones in hu-
man plasma did not change after repeated freeze–thaw cycles
at room temperature [102]. After four freeze–thaw cycles at
4 °C only 0.5 % (4/706) of metabolite ions changed signifi-
cantly in our recently published non-targeted metabolomics
approach [25]. However, the sensitivity of individual samples
to repeated freeze–thaw cycles varies, which led us to con-
clude that the stability of serum or plasma is also dependent on
the donors [25]. Macromolecules including DNA, RNA, and
proteins are also affected by frequent refreezing [94, 99]. The
DNAyield was reported to decrease by 25% after one freeze–
thaw cycle at room temperature [100]. The metabolite content
may be changed by the depositing of protein during freeze–
thaw cycles. To avoid potential effects from repeated freeze–
thaw cycles it is recommended to divide the samples into
small aliquots before storage.
Sample pretreatment for mass-spectrometry analysis
Sample pretreatment is the final preanalytical step, and usually
takes place in the laboratory of the analytical (bio)chemist.
Commonly this step is highly standardized and is less error-
prone; however, it is still critical. In particular, inexperienced
scientists can be overwhelmed by the huge number of differ-
ent sample-pretreatment procedures in the literature. The main
steps of blood pretreatment for metabolomics include
quenching, deproteinization, and extraction. Organic solvents,
ultrafiltration, and solid-phase extraction (SPE) are commonly
used methods for protein precipitation [103]. In particular,
organic solvents including acetonitrile, methanol, chloroform,
etc. can be used for quenching and for highly efficient extrac-
tion [104] of, e.g., polar metabolites [105] and lipids [106].
Fig. 5 illustrates the strategy using methyl tert-butyl ether
(MTBE), methanol, and water to extract metabolites from
tissues, which can effectively extract polar and non-polar me-
tabolites simultaneously. This method is also suitable for the
preparation of blood samples [106]. Each of these procedures
(i.e. organic solvents, ultrafiltration, and SPE) has its strengths
but also has limitations, e.g. the loss of one or several sub-
classes of metabolite as a result of their individual chemical
characteristics.
Fig. 5 The development of a novel sample-preparation method for meta-
bolomics. Using the solvent system MTBE–methanol–water, polar and
non-polar metabolites could be effectively simultaneously extracted from
a limited amount of tissue. Themethod can also be used in the preparation
of blood samples. (Reprint from J Chromatogr A 1298:9–16, License
number 3526350373512)
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Critical variables for solvent extractions and SPE are the
solvent type, pH, and temperature. For SPE the selected solid
phase defines which metabolite classes will be reduced or
even lost. However, SPE can also be used to support the pro-
filing of low-abundance metabolites by concentrating such
compounds and reducing the concentration of high-
abundance metabolites.
Keeping the sample pretreatment for mass-spectrometry
metabolomics analysis as simple as possible guarantees the
highest reproducibility. We suggest deproteinization by the
addition of an organic solvent followed by centrifugation
under highly standardized conditions, because it is simple
and the metabolite coverage is satisfactory. This is a wide-
ly accepted, common procedure for metabolomics-sample
pretreatment [107]. Another very important, simple, but
less respected procedure in this context is to thaw the
body fluids in iced water and not at room temperature
(see section BThe effect of freezing and thawing^). The
samples should be kept cooled at all steps to guarantee
high sample quality. In general, sample pretreatment for
mass-spectrometry analysis is the least critical pre-
analytical step because it is performed by analytical ex-
perts and can be highly standardized, in contrast with,
e.g., blood drawing under highly variable clinical
conditions.
Preanalytical SOP for blood in metabolomics
The continually increasing number of metabolomics applica-
tions in clinical research has led to an increasing demand for
preanalytical SOPs to standardize the collection, transporta-
tion, preparation, and storage of clinical samples [108]. Such
SOPs have been commonly used during clinical trials [24] and
they are of great importance for targeted and nontargeted clin-
ical metabolomics studies [25, 107, 109]. However, to evalu-
ate the stability of every single ion mass or metabolite detect-
able by non-targeted metabolomic analysis of blood under all
possible clinical conditions is a very challenging task. There-
fore, the current preanalytical SOPs are established on the
basis of systematic assessments of the acquired data under
different preanalytical model conditions, investigating the
most critical steps in this complex, error-prone process. As
mentioned above, unsupervised modeling, for example
PCA, is commonly used to evaluate individual variation of
samples. Minor factors will not lead to clustering of samples
in the PCA score plot; for example, in Fig. 3 samples from the
same donor clustered together, whereas the effect of
preanalytical treatment (placing in iced water) was not obvi-
ous. According to the nonparametric test and false-discovery-
rate (FDR) correction, a few variables will still inevitably un-
dergo statistically significant changes [25]. Therefore, the ob-
jective of a practical SOP should be to guarantee the stability
of most but not all metabolites of the metabolome (e.g.
≥98 %), which should be achievable. Suggestions for an
SOP can be found in Ref. [25].
Conclusions
In summary, the preanalytical procedures of blood sampling
and processing may have apparent and strong effects on the
results of metabolomics studies. Taking into account the var-
iance in the population, preanalytical aspects include several
steps, from study design to sample collection, transportation,
and storage. The preanalytical challenges for metabolomics of
blood are mainly caused by two factors: the stability of me-
tabolites and the metabolic action of cells in the sample col-
lection tube. Therefore, SOPs describing the preanalytical pro-
cess must take into account all possible aspects, including,
e.g., the choice of tubes and tips. Because metabolomics al-
ways focuses on the changes after biological perturbation, it is
of great importance that the preanalytical processes for all
enrolled samples are performed as accurately as possible.
Studies focused on preanalytical problems are the basis for
recommendations and SOPs to achieve comparable and repro-
ducible results in metabolomics studies. The principles can be
briefly summarized as follows:
1. For pilot metabolomics studies analyzing a limited num-
ber of samples, carefully considered study design is
mandatory.
2. Before the start of a study the plastic blood-collection
tubes and plastic pipette tips (for sample pipetting)
intended for use must pass a chemical-noise test by MS
analysis.
3. Hemolytic samples, which can be identified by the levels
of free hemoglobin, should be excluded from a study.
4. Collected blood samples (for plasma generation) should
be placed at once in iced water after drawing, and blood
intended for serum preparation should be placed in iced
water immediately after 30 min clotting at room
temperature.
5. Prompt (within 30 min) separation of blood cells from
plasma by centrifugation at 4 °C is ideal, but storage of
whole blood for a maximum of 4 h in iced water before
centrifugation is acceptable and should be feasible in al-
most all clinical studies.
6. Samples should be stored at −80 °C or below. Stepwise
freezing is recommended.
7. Repeated freeze–thaw cycles should be avoided.
8. An individual SOP for the sample pretreatment for mass-
spectrometry analysis is recommended, because this pre-
analytical step is not performed at once, e.g. in the clinic,
but in the laboratory of the analytical (bio)chemists.
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